Daurinoline suppressed the migration and invasion of chemo-resistant human non-small cell lung cancer cells by reversing EMT and Notch-1 and sensitized the cells to Taxol.
Sign Up to like & getrecommendations! Published in 2019 at "Environmental toxicology and pharmacology"
DOI: 10.1016/j.etap.2018.12.005
Abstract: Non-small cell lung cancer (NSCLC) is one of the most common malignancies, and Taxol is a cornerstone in the treatment. However, taxol-resistance eventually limits the clinical effects and applications. Daurinoline could restore the sensitivity of… read more here.
Keywords: daurinoline; cell lung; chemo resistant; non small ... See more keywords
Abstract 818: Preclinical studies of the cabazitaxel nanoformulation MPB-1734 support therapeutic application in chemo-resistant solid tumors and synergistic benefit in combination with immune checkpoint inhibitor
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-818
Abstract: Background: Cabazitaxel (CBZ) is a second-generation taxane that has the potential to overcome taxane-resistance due to the low affinity for the P-glycoprotein efflux pump. However, with the high systemic toxicity such as neutropenia and hypersensitivity,… read more here.
Keywords: mpb; synergistic benefit; chemo resistant; mpb 1734 ... See more keywords
Niclosamide is a potential candidate for the treatment of chemo-resistant osteosarcoma
Sign Up to like & getrecommendations! Published in 2023 at "Genetics and Molecular Biology"
DOI: 10.1590/1678-4685-gmb-2022-0136
Abstract: Abstract Chemotherapy is the main treatment option for advanced osteosarcoma, which is the most common type of primary bone malignancy. However, patients develop resistance rapidly and many succumb to the disease. Niclosamide, an anthelmintic drug,… read more here.
Keywords: osteosarcoma cells; osteosarcoma; chemo resistant; treatment ... See more keywords
Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.815917
Abstract: Toripalimab as a novel PD-1 inhibitor has presented its promising efficacy in patients who developed chemo-refractory carcinomas, whereas no study has ever investigated the effectiveness of toripalimab in chemo-resistant choriocarcinoma. Here we reported the effectiveness… read more here.
Keywords: resistant choriocarcinoma; safety; toripalimab; patients chemo ... See more keywords